Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Metagenomi, Inc. is a biotechnology firm focused on developing gene editing technologies, particularly in the field of therapeutics. The company's unique competitive advantage lies in its proprietary platform that enables precise genomic modifications, targeting rare genetic disorders and enhancing the efficiency of gene therapies. Its operations are primarily based in the United States, with ongoing collaborations in Europe and Asia.
Metagenomi generates revenue primarily through partnerships and collaborations with larger pharmaceutical firms, leveraging its gene editing technology for therapeutic applications. The company has significant pricing power due to its proprietary technology and the high demand for advanced gene therapies, which are often subject to long development timelines and regulatory approvals.
Progress in clinical trials for gene therapies targeting specific genetic disorders
Partnership announcements with major pharmaceutical companies
Regulatory approvals for new gene editing technologies
Market trends in the biotechnology sector, particularly in gene therapy
Regulatory changes that could impact gene editing technologies and their applications
Technological disruption from competing gene editing platforms
Emergence of new competitors with similar or superior gene editing technologies
Potential for large pharmaceutical companies to develop in-house capabilities, reducing reliance on partnerships
Negative cash flow impacting liquidity and ability to fund ongoing R&D
High operational costs leading to sustained losses
moderate - The biotechnology sector can be sensitive to economic cycles, as funding for research and development may fluctuate with economic conditions, impacting partnerships and investments.
Higher interest rates could increase the cost of capital for Metagenomi, affecting its ability to finance R&D projects and partnerships, potentially leading to lower valuations.
minimal - The company has a manageable debt-to-equity ratio of 0.28, indicating limited reliance on external credit.
growth - Investors are likely attracted to the potential for high returns from innovative gene therapies and strategic partnerships.
high - The stock may exhibit high volatility due to the speculative nature of biotechnology investments and reliance on clinical trial outcomes.
